Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Papers of the Week
Annotation


Soriano S, Lu DC, Chandra S, Pietrzik CU, Koo EH. The amyloidogenic pathway of amyloid precursor protein (APP) is independent of its cleavage by caspases. J Biol Chem. 2001 Aug 3;276(31):29045-50. PubMed Abstract


Corresponding Author: Salvador Soriano
Comments on Paper and Primary News
  Comment by:  Rudy Tanzi (Disclosure), Giuseppina Tesco
Permalink
  I recommend this paper

Seminal studies of LeBlanc (1995) have shown that primary neurons committed to undergo apoptosis by serum-deprivation produced increased amount of Abeta. These findings have been confirmed in cerebellar granule cells (Galli et al., 1998), in retinoic acid-differentiated neuronal NT2 cells (Gervais et al., 1999) and in chick embryo motoneurons (Barnes et al.,1998). Caspase inhibition has been shown to reduce the effect of apoptosis on Abeta levels (LeBlanc, 1999 ; Gervais et al., 1999).

More recently it has been shown that APP is also a substrate for caspase cleavage (Barnes et al., 1998; Gervais et al., 1999; LeBlanc et al., 1999; Pellegrini et al., 1999; Weidemann et al., 1999). Many recombinant caspases have been shown to cleave APP in an in vitro assay and a major caspase site has been identified at D720 (VEVD). Each of the four caspases 3, 6, 7, and 8 are able to cleave APP at D720 in vitro resulting in the release of a fragment containing the last 31 amino-acids of APP (C31) and in the production of APPdeltaC31 (lacking Ala721 to Asn751). APP caspase-mediated cleavage at...  Read more


  Comment by:  Benjamin Wolozin, ARF Advisor (Disclosure)
Permalink
  I recommend this paper

"This provides important information relevant to a continuing debate over the mechanisms underlying production of Ab."

View all comments by Benjamin Wolozin

  Comment by:  Eddie Koo, ARF Advisor
Permalink
  I recommend this paper

The point of our paper was the surprising result from Gervais and colleagues that caspase cleavage of APP resulted in more, rather than less, A-beta. The five fold increase in A-beta was striking, making it comparable to the effects of the APP "Swedish" mutation. The authors built a nice hypothesis that caspase cleavage results in more A-beta, then more A-beta toxicity, more caspase cleavage, and so on, leading to an escalating cycle that kills neurons in Alzheimer's disease. The problem is that it did not make sense from the standpoint of current knowledge of A-beta production through the endocytic pathway, a step that requires an intact APP c-terminal tail. Our results did confirm our expectation that caspase cleavage lead to a loss rather than an increase in A-beta. We were careful to use not only our usual CHO cell line but also the B103 cells used by Gervais and colleagues, eliminating the variable of cell line differences. However, we really couldn't explain their results other than it not fitting current model of A-beta generation. The review does correctly point out...  Read more
  Submit a Comment on this Paper
Cast your vote and/or make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
 

REAGENTS/MATERIAL:
Chinese Hamster Ovary (CHO) and Rat Neuronal derived (B103) cells. CHO lines expressing wild type APP751 or truncated forms lacking the cytosolic tail APPDC or the C terminal 31 amino acids APPDC31 have been dscribed in Koo et al, Perez RG et al, Lu DC et al. APPDC15 was generated by PCR mutagenesis methods and transfected into CHO cells with Fugene-6 reagent (Roche Diagnostics Corp). Monoclonal Abs 5A3 and 1G7 against the mid-region of APP and 26D6 against Ab 1-12. 26D6 is a gift from Dr. M. Kounnas. Polyclonal Abs R3134 generated against Ab22-41 and a664 directed against APP695 residues 657-664. R3134 is a gift from Dr. J. Buxbaum. a664 is end-specific and only recognizes APP when it has been cleaved after residue 664.

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad